Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Trial to Evaluate the Safety and Immunogenicity of an Influenza Vaccination Strategy Including a H3N2 M2SR Prime Followed by a Seasonal Quadrivalent Inactivated Vaccine Boost in a Pediatric Population 9-17 Years Old

Next Previous
Trial Profile

A Phase I Trial to Evaluate the Safety and Immunogenicity of an Influenza Vaccination Strategy Including a H3N2 M2SR Prime Followed by a Seasonal Quadrivalent Inactivated Vaccine Boost in a Pediatric Population 9-17 Years Old

Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Dec 2018

At a glance

  • Drugs H3N2 M2SR influenza vaccine-FluGen (Primary) ; Influenza virus vaccine
  • Indications Influenza A virus infections
  • Focus Adverse reactions

    • Most Recent Events

    • 22 Sep 2018 New trial record
    • 17 Sep 2018 According to a FluGen media release, the VTEUs are funded by NIAID through contract number HHSN272201300021.
    • 09 Aug 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top